{"id":"W2531329502","doi":"10.1200/jco.2013.31.15_suppl.3575","title":"Results of a phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim (PEG) in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab (B) for colorectal cancer (CRC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; FOLFOX; FOLFIRI; Internal medicine; Neutropenia; Bevacizumab; Placebo; Clinical endpoint; Colorectal cancer; Gastroenterology; Febrile neutropenia; Regimen; Surgery; Randomized controlled trial; Oncology; Chemotherapy; Irinotecan; Oxaliplatin; Cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002371498,0.001540132,0.002554543,0.0003696271,0.0005986654,0.001057328,0.0007096762,0.002105599,0.008764813],"category_scores_gemma":[0.002926497,0.0007208013,0.001607259,0.0003407976,0.001068703,0.0009432988,0.0003876703,0.002959266,0.001050801],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007432643,"about_ca_system_score_gemma":0.001458092,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007051045,"about_ca_topic_score_gemma":0.001776433,"domain_scores_codex":[0.9992045,0.0004407183,0.00006500588,0.000138211,0.00005064638,0.0001009434],"domain_scores_gemma":[0.9986286,0.0003812471,0.0003273168,0.00008339016,0.0000896429,0.0004898116],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9848231,0.005449926,0.0003808217,0.0002899907,0.0005729641,0.00002308697,0.00002649978,0.0001529657,0.001305236,0.00004249885,0.0005574235,0.006375432],"study_design_scores_gemma":[0.9631667,0.03493007,0.0009671442,0.00001551261,0.0003316733,0.00001282401,0.000006180108,0.0001100254,0.0001463873,0.00005582637,0.0002523852,0.000005274212],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.971078,0.004620111,0.001118213,0.001235748,0.0007858353,0.01377849,0.003026142,0.0001998668,0.004157618],"genre_scores_gemma":[0.981927,0.001823922,0.00162574,0.001434331,0.0003728835,0.008061288,0.001788271,0.00002056743,0.002945904],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008764813,"threshold_uncertainty_score":0.02932119,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1036474043815489,"score_gpt":0.4599664402436699,"score_spread":0.356319035862121,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}